GnRH agonists and antagonists in prostate cancer

摘要

This manuscript describes the System of Objectified Judgement Analysis (SOJA) method applied to gonadotropin-releasing hormone (GnRH) agonists and antagonists in prostate cancer. The following selection criteria were used: efficacy, safety, tolerability, dosage frequency, user-friendly formulation, drug interactions, precaution and documentation. The GnRH agonists goserelin and leuprorelin show the highest scores, mainly based on more extensive documentation compared with the agonists buserelin and triptorelin. The antagonists abarelix and degarelix show low scores, based on a higher incidence of adverse events, a higher dosage frequency, more drug interactions and a more limited documentation compared with the agonists. The availability of a generic formulation of leuprorelin may lead to a reduction in cost.